Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

Findings from the MASTER trial in multiple myeloma could help shape how future treatment decisions are approached for fit, transplant-eligible patients.

A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.

Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.

A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.

Dr Patel discusses post-transplant complications in myeloid disorders, the prevalence of these complications, and the most common ones that may arise, including primary disease relapse, graft-vs-host disease, infection, organ toxicity, persistent cytopenias, and immunosuppression.

Many cancer organizations across the United States and internationally acknowledge a need for in-novative uses of social technology to improve cancer-related support and information provision.

Retinoic acid receptor α, a gene overexpressed in approximately 30% of unfit patients with newly diagnosed acute myeloid leukemia, has emerged as a potential therapeutic target.

The addition of orteronel to androgen deprivation therapy vs bicalutamide improved progression-free survival and prostate-specific antigen response in patients with metastatic hormone-sensitive prostate cancer, but missed the primary end point of overall survival in the phase 2 SWOG-1216 trial.

Afaf E. Osman, MD, discusses the phase 3 SELECT-MDS trial in patients with higher-risk myelodysplastic syndrome.

Christos Vaklavas, MD, discusses the increasing emphasis on investigating tumor biology in breast cancer, plus the evolving treatment landscapes in HER2-positive breast cancer, hormone receptor–positive, HER2-negative breast cancer, and triple-negative breast cancer.

Cristina DeCesaris, MD, discusses classical indications for breast cancer radiation and how these methods are being contextualized in the contemporary treatment era.

Douglas W. Sborov, MD, MS, discusses key data and therapeutic developments that have reshaped the treatment of patients with newly diagnosed and relapsed/refractory multiple myeloma.

Deborah M. Stephens, DO, discusses her approach to treating a patients with chronic lymphocytic leukemia, how CAR T-cell therapy may fit into the treatment paradigm, and the numerous trials that have shown promise in this space.

Deborah M. Stephens, DO, discusses early intervention with targeted agents to improve outcomes in patients with high-risk chronic lymphocytic leukemia.

Deborah M. Stephens, DO, discusses the phase 3 ELEVATE-RR trial comparing the safety and efficacy of acalabrutinib with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Heloisa P. Soares, MD, PhD, discusses the standard of care in metastatic pancreatic cancer.

Heloisa P. Soares, MD, PhD, discusses advances in the management of pancreatic neuroendocrine tumors.

The combination of atezolizumab and cabozantinib elicited encouraging responses, marked by an unprecedented disease control rate, in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, but most strikingly in patients with high-risk features.

Douglas W. Sborov, MD, MS, discusses supportive care approaches for selinexor-associated toxicities in multiple myeloma.

Neeraj Agarwal, MD, discusses the adverse effects associated with belzutifan in patients with renal cell carcinoma.

Heloisa P. Soares, MD, PhD, discusses recent developments in NETS, pancreatic cancer, and GEJ tumors, as well as sequencing strategies aimed at improving patient outcomes across GI cancers.

Douglas W. Sborov, MD, MS, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.

Douglas W. Sborov, MD, MS, discusses mitigating toxicities associated with monoclonal antibodies in multiple myeloma.

Douglas W. Sborov, MD, MS, discusses the toxicities associated with novel therapies in multiple myeloma.

Neeraj Agarwal, MD, discusses the efficacy of intensified androgen deprivation therapy in patients with newly diagnosed, metastatic, hormone-sensitive prostate cancer.

Sonam Puri, MD, discusses recent research on clinically relevant biomarkers in small cell lung cancer. 

Sonam Puri, MD, discusses the rationale to evaluate the real-world multiomic characterization of small cell lung cancer subtypes.

Dr. Masten reflects on the main challenges that arose during the COVID-19 lockdown with regard to surgery in patients with breast cancer, the steps that were taken as the lockdown started to lift, and the changes that have been made with regard to managing patients around the time of surgery and in the operating room.

Christos Vaklavas, MD, discusses the progress that has been made in metastatic HR-positive, HER2-negative breast cancer and potential pathways forward for therapeutic sequencing.